NASDAQ:UNCY Unicycive Therapeutics 3/28/2024 Earnings Report $0.64 +0.03 (+5.22%) Closing price 05/7/2025 04:00 PM EasternExtended Trading$0.63 -0.01 (-0.80%) As of 05/7/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Unicycive Therapeutics EPS ResultsActual EPS-$0.16Consensus EPS -$0.18Beat/MissBeat by +$0.02One Year Ago EPSN/AUnicycive Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUnicycive Therapeutics Announcement DetailsQuarterDate3/28/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsUnicycive Therapeutics' next earnings date is estimated for Monday, May 12, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Unicycive Therapeutics Earnings HeadlinesAnalysts Expect Breakeven For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Before LongMay 7 at 12:54 PM | finance.yahoo.comGuggenheim Initiates Coverage of Unicycive Therapeutics (UNCY) with Buy RecommendationApril 22, 2025 | msn.comThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 8, 2025 | Timothy Sykes (Ad)Unicycive Therapeutics initiated with a Buy at GuggenheimApril 22, 2025 | markets.businessinsider.comUnicycive presents new patient-level data from Phase 2 study of OLCApril 12, 2025 | markets.businessinsider.comUnicycive Therapeutics price target raised to $7.50 from $4 at H.C. WainwrightApril 2, 2025 | markets.businessinsider.comSee More Unicycive Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Unicycive Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Unicycive Therapeutics and other key companies, straight to your email. Email Address About Unicycive TherapeuticsUnicycive Therapeutics (NASDAQ:UNCY), a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.View Unicycive Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Disney Stock Jumps on Earnings—Is the Magic Sustainable?Archer Stock Eyes Q1 Earnings After UAE UpdatesFord Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx BoostPalantir Stock Drops Despite Stellar Earnings: What's Next?Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?Is Reddit Stock a Buy, Sell, or Hold After Earnings Release? Upcoming Earnings Monster Beverage (5/8/2025)Brookfield (5/8/2025)Anheuser-Busch InBev SA/NV (5/8/2025)ConocoPhillips (5/8/2025)Cheniere Energy (5/8/2025)McKesson (5/8/2025)Shopify (5/8/2025)Enbridge (5/9/2025)Petróleo Brasileiro S.A. - Petrobras (5/12/2025)Simon Property Group (5/12/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
